Stock Scorecard
Stock Summary for Ensysce Biosciences Inc (ENSC) - $0.66 as of 11/21/2024 12:03:08 AM EST
Total Score
9 out of 30
Currently on the following lists
None
Tim's Recommendation
Avoid
Growth List Algorithm Criteria for ENSC
Positive earnings growth | |
P/E ratio less than Industry P/E Ratio | |
P/E ratio less than Sector P/E Ratio | |
P/E ratio that is half the growth rate (or less) | |
Positive net cash position the past year and most recent quarter | |
Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
Positive net income past year and 12 trailing months | |
Free cash flow ratio greater than 0 and less than 10 |
Small Cap List Algorithm Criteria for ENSC
Revenue growing by at least 20% average per year over the last 5 years | |
Market Capitalization under 2 billion | |
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months | |
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months | |
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year |
Dividend List Algorithm Criteria for ENSC
Declared an ex-dividend date | |
Forward annual dividend rate greater than 2 | |
Positive net cash position the past year and most recent quarter | |
Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
Current ratio most recent quarter greater than 2 | |
Cash Flow per Share greater than Trailing Dividend Rate |
Bonus Criteria for ENSC
P/E ratio less than five-year Average P/E ratio | |
Last Price to 52 Week Low Ratio Less Than 1 | |
Total Cash Per Share > Last Day Price | |
P/S Ratio < 1 | |
P/B Ratio < 1 |
Safety Rating Criteria for ENSC (22 out of 90)
Stock Price Rating (Max of 10) | 1 |
Historical Stock Price Rating (Max of 10) | 10 |
Stock Price Trend (Max of 10) | 1 |
Book Value (Max of 10) | 1 |
Book Value to Price (Max of 10) | 0 |
Analyst Buy Ratings (Max of 5) | 0 |
Analyst Strong Buy Ratings (Max of 5) | 0 |
Dividend Yield Percentage (Max of 10) | 0 |
Operating Margin (Max of 10) | 0 |
Trading Volume (Max of 10) | 9 |
Price to Earnings (Max of 10) | 0 |
Latest News for for ENSC
Financial Details for ENSC
Company Overview |
|
---|---|
Ticker | ENSC |
Company Name | Ensysce Biosciences Inc |
Country | USA |
Description | Ensysce Biosciences, Inc., a clinical-stage biotechnology company, is dedicated to the development of various prescription drugs. The company is headquartered in La Jolla, California. |
Sector Name | REAL ESTATE & CONSTRUCTION |
Industry Name | BLANK CHECKS |
Most Recent Quarter | 9/30/2024 |
Next Earnings Date | N/A |
Stock Price History |
|
Last Day Price | 0.66 |
Price 4 Years Ago | 2,984.33 |
Last Day Price Updated | 11/21/2024 12:03:08 AM EST |
Last Day Volume | 1,172,679 |
Average Daily Volume | 56,086,410 |
52-Week High | 2.06 |
52-Week Low | 0.14 |
Last Price to 52 Week Low | 371.43% |
Valuation Measures |
|
Trailing PE | N/A |
Industry PE | 117.20 |
Sector PE | 66.35 |
5-Year Average PE | 6.12 |
Free Cash Flow Ratio | 3.14 |
Industry Free Cash Flow Ratio | 225.17 |
Sector Free Cash Flow Ratio | 124.65 |
Current Ratio Most Recent Quarter | 3.24 |
Total Cash Per Share | 0.21 |
Book Value Per Share Most Recent Quarter | -0.10 |
Price to Book Ratio | 1.93 |
Industry Price to Book Ratio | 7.40 |
Sector Price to Book Ratio | 11.98 |
Price to Sales Ratio Twelve Trailing Months | 9.23 |
Industry Price to Sales Ratio Twelve Trailing Months | 0.47 |
Sector Price to Sales Ratio Twelve Trailing Months | 4.06 |
Analyst Buy Ratings | 0 |
Analyst Strong Buy Ratings | 0 |
Share Statistics |
|
Total Shares Outstanding | 19,574,000 |
Market Capitalization | 12,918,840 |
Institutional Ownership | N/A |
Dividends |
|
Ex-Dividend Date | N/A |
Last Dividend Amount | 0.00 |
Current Dividend Amount | 0.00 |
Total Years Dividend Increasing | N/A |
Trailing Annual Dividend Rate | 0.00 |
Trailing Annual Dividend Yield | 0.00% |
Forward Annual Dividend Rate | 0.00 |
Forward Annual Dividend Yield | 0.00% |
5-Year Dividend Payments Count | 0 |
3-Year Average Dividend Yield | 0.00% |
5-Year Average Dividend Yield | 0.00% |
1-Year Dividend Growth Rate Percentage | 0.00% |
3-Year Dividend Growth Rate Percentage | 0.00% |
5-Year Dividend Growth Rate Percentage | 0.00% |
All-Time Dividend Growth Rate Percentage | 0.00% |
Dividend Payout Ratio | N/A |
Income Statement |
|
Quarterly Earnings Growth YOY | 0.00% |
Annual Earnings Growth | 56.09% |
Reported EPS 12 Trailing Months | -1.93 |
Reported EPS Past Year | -0.70 |
Reported EPS Prior Year | -5.30 |
Net Income Twelve Trailing Months | -7,925,909 |
Net Income Past Year | -10,613,074 |
Net Income Prior Year | -24,172,292 |
Quarterly Revenue Growth YOY | -62.90% |
5-Year Revenue Growth | 46.92% |
Operating Margin Twelve Trailing Months | -10.76 |
Balance Sheet |
|
Total Cash Most Recent Quarter | 4,153,592 |
Total Cash Past Year | 1,123,604 |
Total Cash Prior Year | 3,147,702 |
Net Cash Position Most Recent Quarter | 3,766,416 |
Net Cash Position Past Year | 268,907 |
Long Term Debt Past Year | 854,697 |
Long Term Debt Prior Year | 4,717,104 |
Total Debt Most Recent Quarter | 387,176 |
Equity to Debt Ratio Past Year | -0.61 |
Equity to Debt Ratio Most Recent Quarter | 0.95 |
Total Stockholder Equity Past Year | -322,858 |
Total Stockholder Equity Prior Year | -3,714,444 |
Total Stockholder Equity Most Recent Quarter | 6,908,210 |
Free Cash Flow |
|
Free Cash Flow Twelve Trailing Months | -8,540,485 |
Free Cash Flow Per Share Twelve Trailing Months | -0.44 |
Free Cash Flow Past Year | -10,779,984 |
Free Cash Flow Prior Year | 0 |
Options |
|
Put/Call Ratio | 0.00 |
Has Options | False |
Liquidity Rating | |
Technical Analysis |
|
Yahoo Finance Chart | Yahoo Finance Chart |
MACD | 0.09 |
MACD Signal | 0.10 |
20-Day Bollinger Lower Band | 0.11 |
20-Day Bollinger Middle Band | 0.42 |
20-Day Bollinger Upper Band | 0.72 |
Beta | 0.64 |
RSI | 60.56 |
50-Day SMA | 63.71 |
150-Day SMA | 0.00 |
200-Day SMA | 559.07 |
System |
|
Modified | 11/21/2024 12:03:54 AM EST |